The Systemic Use of Procaine in the Treatment of the Elderly: A Review

Journal of the American Geriatrics Society

Volumn 25, Issue 1, 1977, Pages 1-19

  Ostfeld, Adrian ^a,b,c,d,e   Smith, Cedric M ^a,b,c,d,e   Stotsky, Bernard A ^a,b,c,d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d St Elizabeth's Hospital of Boston ^*  (United States)

^e Department of Otolaryngology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROCAINE;

AGE; AGED; AGING; CHRONIC DISEASE; DRUG EFFICACY; DRUG THERAPY; GERIATRICS; THERAPY;

EID: 0017336335     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1977.tb00917.x     Document Type: Article

References (148)

1. The cholinergic receptor protein in its membrane environment
2. Effects of local anesthetics and calcium on the interaction of cholinergic ligands with the nicotinic receptor protein from Torpedo marmorata
3. Discussion of rate and site of action of local anesthetics in myelinated nerve fibers
4. The common mode of action of three agents that decrease the transient change in sodium permeability in nerves
5. Local anesthetics and the electric properties of phospholipid bilayer membranes
6. The site of action and active form of local anesthetics. I. Theory and pH experiments with tertiary compounds
7. On the mode of action of local anesthetics
8. The membrane actions of anesthetics and tranquilizers
9. Effects of pH gradients on action of procaine and lidocaine in intact and desheathed nerves
10. Effects of procaine on electrical properties of squid axon membrane
11. Arrest of rapid axoplasmic transport in a sensory nerve in vivo by ligature or lidocaine treatment
12. Drug‐induced alterations in respiration of rat brain cortex and striatum slices in a carbon dioxide‐bicarbonate‐buffered medium
13. Competitive action of calcium and procaine on lobster axon
14. Electrochemical aspects of physiological and pharmacological action in excitable cells
15. Responses in dental nerves of dogs to tooth stimulation and the effects of systemically administered procaine, lidocaine, and morphine
16. Depression of afferent activity originating in muscle spindles induced by mephenesin, procaine and caramiphen
17. Effects of procaine pentobarbital and halothane on synoptic transmission in the central nervous system
18. Central physiological effects of experimental intravenous procaine hydrochloride
19. CNS effects of local anesthetics only partially dependent on biogenic amine mechanisms
20. Effect of temporary septal dysfunction on conditioning and performance of fear responses in rats
21. Procaine injections into MFB‐LHA during septal and preoptic self‐stimulation
22. Effects of intracranial chemical injections upon self‐stimulation in the rat
23. The fate of procaine in man following its intravenous administration and methods for the estimation of procaine and diethylaminoethanol
24. Procaine (Gerovital H3) therapy: mechanism of inhibition of monoamine oxidase
25. Possible rationale for procaine (Gerovital H3) therapy in geriatrics: inhibition of monoamine oxidase
26. Gerovital H3, monoamine oxidases and brain monoamines
27. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines
28. (a) Theoretical and practical aspects of chemotherapeutic techniques in the retardation of the aging process
29. The effects of a European procaine preparation in an aged population
30. Gerovital‐H3: a review of the literature
31. Pharmacology of depression in the aged: evaluation of Gerovital H3 as an antidepressant drug
32. Deanol: a solution for tardive dyskinesia
33. Deanol in the treatment of levodopa‐induced dyskinesias
34. Dimethylaminoethanol in tardive dyskinesia
35. Stimulant effect of 2‐dimethylaminoethanol — possible precursor of brain acetylcholine
36. Rapid and gentle pharmacotherapy of depression
37. Deanol and behavior disorders in children: a critical review of the literature and recommended future studies for determining efficacy
38. Absence of influence of procaine (Novocain)
39. A psychopharmacological evaluation of 2‐diethylamino‐ethyl‐paraaminobenzoate (procaine)
40. Procaine (Novocain) treatment of patients with senile and arteriosclerotic brain disease
41. Prolonged procaine therapy in geriatric psychiatric patients
42. H‐3 (procaine hydrochloride) therapy in aging institutionalized patients: an interim report
43. Badonia psychologiazne nad stanem psychicciznyn packentaro leczonyck geriokaina
44. Gerovital H3 in the treatment of the depressed aging patient
45. A trial of Gerovital in depression during senility
46. Sobre la accion revitalizadora de la procaine
47. Stati ipnotici della corteccia cerebrale e sindromi malinconiche involutive; considerazioni su alcuni casi in corso de tratamento procainico (Faltore H3)
48. La posibilita terapeutiche della novovaine nelle psicosi senili
49. Effetti del trattemento novocainico prolungato sul efficienza intellettiva in soggetti di eta avanzata
50. On a new method of treatment of the devitalized general psychophysical state
51. Ensayo de la combinasion procaina paba en la prolaxis y tratamiento de los procesos de involusion
52. Sulla terapia procainica della vecchiaia
53. A report on gerascan and rejuvitol
54. Leceni depresivnich stain injekcemi prokaimi
55. Procaine therapy in old age and other disorders (Novocain factor H3)
56. Our experience with treatment of diseases of aging with procaine by the Parhon and Aslan method
57. Les traitements de la sénilite
58. Contributo allo studio del trattamento della forme neuropsichiatriche dell eta senile: la terapia procainica
59. La terapia con gerovital H3 nelle malatie della senescenza e delia vecchiaia
60. Considerazion vecchi e nuore sulle considette “terapie de ringioranimento
61. An evaluation of procaine in geriatric patients in a mental hospital
62. Novocaine H3 in geriatrics
63. An investigation of Gerovital H3 (procaine hydrochloride) in treatment of organic brain syndrome
64. Evaluation of chronically ill patients treated for one year with procaine
65. The effect of procaine on orientation, attention, memory, and weight of aged psychiatric patients
66. Trial of procaine in old age and chronic degenerative disorders
67. Trials of procaine in aged patients
68. A clinical trial of procaine hydrochloride
69. Trial of procaine in the aged
70. Administration of procaine in aged individuals: exploratory study
71. A controlled trial of “Gerioptil
72. The effects of a European procaine preparation in an aged population. I. Psychological effects
73. A new method for the prophylaxis and treatment of aging with Novocain — eutrophic and rejuvenating effects
74. Therapeutica de la vejez
75. Traitement intraartériel à la procaine dans les arthrites and les arthroses
76. Erfahrungen auf dem Geleit der Behandlung des alternden Menschen
77. Les effects de la procaine dans l'arthrite expérimental provoquée chez les rats blanc
78. Ou en sommes‐nous des spécialites gériatriques françaises
79. Ubiquité et atoxicite de la procaine en thérapeutique
80. Erste Erfahrung mit Novocainbehandlung alter Menschen
81. La thérapie par la procaine dans la sénescence et autries troubles trophique (Novocain‐facteur H3)
82. A review of procaine therapy in elderly individuals
83. Revision of diagnostic criteria for rheumatoid arthritis
84. Multiclinic trials in arthritis
85. Hydroxychloroquine sulfate in rheumatoid arthritis; a six month double blind trial
86. Nossa experiencia com a Novocaina (Factor H3)
87. Quoted by M Rutowisch
88. Letter to the editor
89. The effect of intravenous injections of Novocain on the blood system
90. Le traitement de l'ictus par la procaine substance H3
91. A Novocaina em clinica
92. La procaine action eutrophique en gerontologie
93. The therapeutics of old age: the action of procaine
94. La thérapeutique de la viellesse
95. Traitement de l'acrocyanose par la procaine injectée par voie intraarterial
96. Sur une expériense de 86 cas de traitement de troubles de la sénescence par la procaine
97. A sphygmomanometer for epidemiologists
98. Der Einflus der Gerovital H3 auf die Produkt vitat der Hubner der Rhode‐Island‐Rasse
99. Réflexions sur les thérapeutiques gerontologiques
100. Statistical survey of morbidity per sexes in 30,210 cases at the Bucharest Institute of Geriatrics
101. Die Verschiebungen der Kapillarpermeabilitat bei Artheriosclerose
102. Influenta virstei patosclerozie si tratamentului procaine asupra permeabilitatii capilare differentiate
103. Studien über die Verschiebungen der Kapillarpermeabilitat mit zunchmendem Alter
104. Aspecte privind studilul biologiei batrinetti
105. Rapport sur la pathogénie de l'atherosclerose (avec considérations spéciales sur les trouble de perméabilité de la paroi‐vasculaire)
106. L'action de la procaine (substance H3) au cours de l'atherosclerose expérimentale chez les lapins
107. Biochemische und physiologische Alterskriterien und ihre Veranderung in Laufe der Behandlung, als Rehabilitations Merkmale aus der Erfabrung des Institute fur Geriatrie in Bukarest
108. On Novocain therapy of illness with consideration of serum lipids
109. La prophylaxie médicamentens du viellessement au Gerovital H3
110. Percutaneous procaine blockage (PPB) in diseases of aging and geriatrics
111. Traitement prophylactique et thérapeutique de l'insuffisance circulatoire cérébrale au Gerovital H3
112. Zur oralen procain‐therapie
113. Apoplectic ictus
114. Les affections cardiovasculaire chez les personnes ages et la médication biotrophique au Gerovital H3
115. Treatment of certain diseases of elderly persons with a 2% solution of Novocain
116. Jenacain‐Behandlung bei inneren Erkrankungen im Alter
117. Fat transport in lipoproteins. An integrated approach to mechanisms and disorder
118. Familial hyperlipoproteinemia
119. A physician's guide to hyperlipidemia
120. L'aspect de la maladie ulcereuse et les résultats thérapeutiques par décades d'age
121. Associao terapeutica de acetato de prednisolana com o cloridrato de novocaina na asma
122. Ergebnisse der Novokain‐Behandlung bei dysmetabolischen Arthropathien